Badarch, Bat-Ireedui
Loading...
Товч нэр
Badarch, Bat-Ireedui
Бүтэн нэр
Badarch Bat-Ireedui
Латин нэр
Badarch Bat-Ireedui
Албан тушаал
Судлаач
14 results
Now showing 1 - 10 of 14
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Post Liver Transplantation Renal Impairment: Experience With the First 100 Cases in a Single Center in Mongolia(2022); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Renal Dysfunction After Liver Transplantation: a Single Center Study(Mongolian National University of Medical Sciences, 2021-12-31); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hepatic arterial reconstruction using saphenous vein graft interposition for living donor liver transplantationBatsaikhan BAT-ERDENE*, Bat-Ireedui BADARCH, Sergelen ORGOI, Erdene SANDAG, Batsaikhan BATSUURI, Urnult GANBOLD, Otgonbayar SETEVDORJ. Ann Hepatobiliary Pancreat Surg 2023;27:S313. https://doi.org/10.14701/ahbps.2023S1.EP-46 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Nonsurgical treatment of abdominal compartment syndrome in a patient following living donor liver transplantation: a case report(The Korean Society for Transplantation, 2022-11-17); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Massive gastrointestinal bleeding following living donor liver transplantation: a case report(The Korean Society for Transplantation, 2022-11-17); ; ; Sainbyan, Tamir - Some of the metrics are blocked by yourconsent settings
Item type:Publication, BUILDING A SELF-SUFFICIENT LIVER TRANSPLANT PROGRAM IN MONGOLIA(Ovid Technologies (Wolters Kluwer Health), 2020-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact factors leading to renal impairment after liver transplant surgery: a single center study(2022-11-14); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P.389: No difference in recurrent hepatocellular carcinoma rates in liver transplanted patients receiving mTOR inhibitors compared to non-mTOR group.(Wolters Kluwer, 2024-09-01) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P.402: The role of complement C4 and Alt level for acute rejection after liver transplantation.(Wolters Kluwer, 2024-09-01); ; ; ; Acute liver graft rejection is still a common complication after liver transplantation. Diagnosis of acute cellular rejection (ACR) requires a liver biopsy with attendant expense, and risk, especially for developing countries. Measurements of serum complement components C3 and C4 are useful in the diagnosis and monitoring of immune complex disease. The normal adult range of C4 is 20-50mg/dl. Low levels of C4 strongly suggest immune complex disease. The combination C4 and ALT levels are highly predictive of acute cellular rejection (ACR) in liver transplant recipients. A lowered concentration or the complete absence of C4 occurs in immunocomplex diseases, systemic lupus erythematosus (SLE), autoimmune thyroiditis and juvenile dermatomyositis. Patients and Methods: Our study has two groups, one group comprised 8 liver transplant recipients, who has predictive diagnosis of ACR. The other group comprised 8 liver transplant recipients, who has not prediction of ACR. Pathologist evaluated the ACR by Banff grading schema. Serum C4 was checked Cobas 6000/c501/ analyzer. Results: ACR patients had an average of C4 ≤ 0.22 gm/L test, ALT ≥ 124 IU/ml. The patients without ACR had an average of C4 ≥0.61 gm/L test, ALT ≤ 87 IU/ml. The ACR patients had done needle biopsy, which showed liver rejection.Conclusion: To detect serum C4 in blood is a relatively non-invasive, inexpensive, easy to measure and quick marker. Especially for developing countries like Mongolia, preliminary diagnosis of ACR, which revealed decreasing C4 and increasing ALT convenient to biopsy results. Organ Transplantation Team of Mongolia.